AR032379A1 - Derivados de 1,2,4,5-tetrahidro-benzo(d)azepina-pirazina y triazina y derivados de 1,2,4,5-tetrahidro-tieno(d)azepina-pirazina y triazina - Google Patents
Derivados de 1,2,4,5-tetrahidro-benzo(d)azepina-pirazina y triazina y derivados de 1,2,4,5-tetrahidro-tieno(d)azepina-pirazina y triazinaInfo
- Publication number
- AR032379A1 AR032379A1 ARP010105926A ARP010105926A AR032379A1 AR 032379 A1 AR032379 A1 AR 032379A1 AR P010105926 A ARP010105926 A AR P010105926A AR P010105926 A ARP010105926 A AR P010105926A AR 032379 A1 AR032379 A1 AR 032379A1
- Authority
- AR
- Argentina
- Prior art keywords
- lower alkyl
- chr
- azepina
- pirazina
- triazina
- Prior art date
Links
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 4
- 125000003342 alkenyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 abstract 1
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Otolaryngology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00128329 | 2000-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR032379A1 true AR032379A1 (es) | 2003-11-05 |
Family
ID=8170787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010105926A AR032379A1 (es) | 2000-12-22 | 2001-12-20 | Derivados de 1,2,4,5-tetrahidro-benzo(d)azepina-pirazina y triazina y derivados de 1,2,4,5-tetrahidro-tieno(d)azepina-pirazina y triazina |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US6586422B2 (enExample) |
| EP (1) | EP1345609B1 (enExample) |
| JP (1) | JP4077319B2 (enExample) |
| KR (1) | KR100545906B1 (enExample) |
| CN (1) | CN1260226C (enExample) |
| AR (1) | AR032379A1 (enExample) |
| AT (1) | ATE297734T1 (enExample) |
| AU (1) | AU2002216095B2 (enExample) |
| BR (1) | BR0116378A (enExample) |
| CA (1) | CA2432077C (enExample) |
| DE (1) | DE60111568T2 (enExample) |
| DK (1) | DK1345609T3 (enExample) |
| ES (1) | ES2243400T3 (enExample) |
| MX (1) | MXPA03005515A (enExample) |
| PT (1) | PT1345609E (enExample) |
| WO (1) | WO2002051418A1 (enExample) |
| ZA (1) | ZA200304557B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7678363B2 (en) | 2005-08-26 | 2010-03-16 | Braincells Inc | Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs |
| EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
| WO2007047978A2 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| AU2006308889A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | GABA receptor mediated modulation of neurogenesis |
| MX2008009178A (es) * | 2006-01-19 | 2008-12-05 | Athersys Inc | Tiofenil y pirrolil acepinas como ligandos del receptor de serotonina 5-ht2c y sus usos. |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| WO2007134077A2 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
| CA2651813A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| CA2662491A1 (en) | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| KR101100864B1 (ko) * | 2009-06-12 | 2012-01-02 | 양준호 | 자동차 광택기용 광택패드 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3136654A1 (de) | 1981-09-16 | 1983-03-31 | Zahnradfabrik Friedrichshafen Ag, 7990 Friedrichshafen | Linearverschieblicher arbeitsarm, insbesondere fuer handhabungsgeraete |
| EP1059090A4 (en) * | 1998-03-03 | 2002-02-27 | Yamanouchi Pharma Co Ltd | DRUGS AGAINST BLEEDING OF THE BRAIN |
| PT1117403E (pt) * | 1998-10-02 | 2004-04-30 | Sibia Neurosciences Inc | Antagonistas de mglurs para o tratamento da dor e ansiedade |
| GB9823847D0 (en) * | 1998-11-02 | 1998-12-23 | Lilly Co Eli | Pharmaceutical compounds |
| EP1074549B1 (en) * | 1999-08-06 | 2003-11-19 | F. Hoffmann-La Roche Ag | Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors |
| ES2209728T3 (es) * | 1999-08-06 | 2004-07-01 | F. Hoffmann-La Roche Ag | Tetrahidro-benzo(d)azepinas y su uso como antagonistas de receptores de glutamato metabotropico. |
-
2001
- 2001-12-11 CA CA2432077A patent/CA2432077C/en not_active Expired - Fee Related
- 2001-12-11 WO PCT/EP2001/014527 patent/WO2002051418A1/en not_active Ceased
- 2001-12-11 MX MXPA03005515A patent/MXPA03005515A/es active IP Right Grant
- 2001-12-11 ES ES01271999T patent/ES2243400T3/es not_active Expired - Lifetime
- 2001-12-11 DE DE60111568T patent/DE60111568T2/de not_active Expired - Lifetime
- 2001-12-11 BR BR0116378-7A patent/BR0116378A/pt not_active IP Right Cessation
- 2001-12-11 CN CNB018222099A patent/CN1260226C/zh not_active Expired - Fee Related
- 2001-12-11 JP JP2002552562A patent/JP4077319B2/ja not_active Expired - Fee Related
- 2001-12-11 PT PT01271999T patent/PT1345609E/pt unknown
- 2001-12-11 EP EP01271999A patent/EP1345609B1/en not_active Expired - Lifetime
- 2001-12-11 AU AU2002216095A patent/AU2002216095B2/en not_active Ceased
- 2001-12-11 KR KR1020037008488A patent/KR100545906B1/ko not_active Expired - Fee Related
- 2001-12-11 AT AT01271999T patent/ATE297734T1/de active
- 2001-12-11 DK DK01271999T patent/DK1345609T3/da active
- 2001-12-12 US US10/020,680 patent/US6586422B2/en not_active Expired - Fee Related
- 2001-12-20 AR ARP010105926A patent/AR032379A1/es unknown
-
2003
- 2003-06-11 ZA ZA200304557A patent/ZA200304557B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1487831A (zh) | 2004-04-07 |
| ATE297734T1 (de) | 2005-07-15 |
| DE60111568D1 (de) | 2005-07-21 |
| MXPA03005515A (es) | 2003-09-25 |
| AU2002216095B2 (en) | 2005-12-01 |
| KR100545906B1 (ko) | 2006-01-26 |
| PT1345609E (pt) | 2005-08-31 |
| CN1260226C (zh) | 2006-06-21 |
| EP1345609B1 (en) | 2005-06-15 |
| WO2002051418A1 (en) | 2002-07-04 |
| ES2243400T3 (es) | 2005-12-01 |
| CA2432077A1 (en) | 2002-07-04 |
| DK1345609T3 (da) | 2005-10-03 |
| CA2432077C (en) | 2011-01-18 |
| EP1345609A1 (en) | 2003-09-24 |
| BR0116378A (pt) | 2003-10-28 |
| KR20030062444A (ko) | 2003-07-25 |
| JP2004517850A (ja) | 2004-06-17 |
| DE60111568T2 (de) | 2006-05-11 |
| JP4077319B2 (ja) | 2008-04-16 |
| US6586422B2 (en) | 2003-07-01 |
| ZA200304557B (en) | 2004-09-13 |
| US20020123488A1 (en) | 2002-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR032379A1 (es) | Derivados de 1,2,4,5-tetrahidro-benzo(d)azepina-pirazina y triazina y derivados de 1,2,4,5-tetrahidro-tieno(d)azepina-pirazina y triazina | |
| ES2221440T3 (es) | Derivados de acido aminofenoxiacetico como neuroprotectores. | |
| PE20061298A1 (es) | Compuestos derivados de dihidrobenzofurano como agonistas del receptor de serotonina 5-ht2c | |
| PE20061297A1 (es) | Compuestos derivados de cromano y cromeno moduladores del receptor de serotonina 5-ht2c | |
| PE1998A1 (es) | DERIVADOS DE BENZO [g] QUINOLINA | |
| AR033046A1 (es) | Derivados de 4,5-dihidro-1h-pirazol que tienen actividad antagonista de cb1, composicion farmaceutica y metodos de preparacion | |
| UY27551A1 (es) | Derivados de benzotiazol | |
| AR010080A1 (es) | Derivados de 1,2,3,4-tetrahidronaftaleno | |
| AR011623A1 (es) | Compuestos de sulfonamidas, procedimiento para prepararlos y composiciones farmaceuticas para potenciar las funciones de los glutamatoreceptores enmamiferos. | |
| AR021534A1 (es) | Derivados de 1,4-diazabiciclo[3.2.2]nonano, su preparacion y su aplicacion en terapeutica | |
| PT885210E (pt) | Compostos triciclicos que possuem afinidade de ligacao para receptores de melatonina sua producao e utilizacao | |
| PE20031011A1 (es) | Derivados de dihidrobenzodiazepin-2-ona-iii | |
| PE20081447A1 (es) | Compuestos y composiciones como inhibidores de la proteina cinasa | |
| ATE252575T1 (de) | Indole und 2,3-dihydroindolderivate, ihre herstellung und verwendung | |
| PE20060590A1 (es) | COMPUESTOS ESTEROIDALES 15ß-SUSTITUIDOS CON ACTIVIDAD SELECTIVA DEL RECEPTOR DE ESTROGENOS | |
| PE20030610A1 (es) | Derivados de 3-azabiciclo[3.1.0]hexano con afinidad a los receptores opioides | |
| AR029400A1 (es) | Derivados de isoxazolcarboxamida, un metodo para su preparacion y una composicion farmaceutica que los comprende | |
| PE106099A1 (es) | Uso de derivados hidroxicumaranonas sustituidos como agentes antitumorales y antimetastasicos | |
| NO20000737L (no) | Tetrahydro <gamma>-karboliner | |
| PE20061144A1 (es) | DERIVADOS DE PIRROLIDINA Y PIPERIDINA ACETILENO COMO ANTAGONISTAS DE LOS RECEPTORES DE GLUTAMATO METABOTROPICO (mGluRs) | |
| AR039122A1 (es) | Derivados de ftalimido como inhibidores de monoamino oxidasa b | |
| PE20001460A1 (es) | DERIVADOS DE PIPERIDINA Y PIPERAZINA COMO INHIBIDORES DE LA FORMACION DEL PEPTIDO ß-AMILOIDE | |
| DK0431579T3 (da) | Substituerede cyclohexener som midler med virkning på centralnervesystemet | |
| AR057197A1 (es) | Derivados de 1, 1-dioxo-tiomorfolinil-indolil-metanona | |
| AR028685A1 (es) | Derivados de indol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |